Micah Hall, MD
Family Medicine · Andover, KSNPI 1194088484
Payments from drug & device makers
Across 244 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$549
- Amgen$404
- GSK$315
- Novo Nordisk$290
- Astellas Pharma US Inc$273
- AstraZeneca$149
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,605100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $549 |
| Amgen | 24 | $404 |
| GSK | 21 | $315 |
| Novo Nordisk | 19 | $290 |
| Astellas Pharma US Inc | 18 | $273 |
| AstraZeneca | 11 | $149 |
| Abbott | 9 | $139 |
| Dexcom, Inc. | 6 | $121 |
| Pfizer | 8 | $119 |
| Lilly USA, LLC | 7 | $109 |
| Johnson & Johnson | 8 | $104 |
| Merck | 7 | $100 |
| Medtronic | 4 | $99 |
| Bayer | 6 | $94 |
| Antares Pharma, Inc. | 5 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $74 |
| Boehringer Ingelheim | 5 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Novartis | 3 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $30 |
| Nevro Corp. | 1 | $28 |
| Amarin Pharma, Inc. | 2 | $24 |
| Organogenesis Inc. | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,605 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 49 | $64,654 |
| TrulicityDulaglutide | 34 | $37,497 |
| OzempicSemaglutide | 28 | $36,035 |
| MounjaroTirzepatide | 28 | $31,954 |
| EliquisApixaban | 13 | $20,631 |
| XareltoRivaroxaban | 13 | $20,392 |
| JanuviaSitagliptin Phosphate | 11 | $18,679 |
| Repatha SureclickEvolocumab | 13 | $17,126 |
| MyrbetriqMirabegron | 14 | $11,806 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,617 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $6,967 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $4,613 |
| Sucralfate | 27 | $4,225 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 16 | $3,511 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $3,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $109 | $69,45162 claims |
| Boehringer IngelheimJardiance | $66 | $64,65449 claims |
| Novo NordiskOzempic | $290 | $36,03528 claims |
| PfizerEliquis | $119 | $20,63113 claims |
| Johnson & JohnsonXarelto | $104 | $20,39213 claims |
| MerckJanuvia | $100 | $18,67911 claims |
| GSKAnoro Ellipta, Shingrix | $315 | $14,12832 claims |
| Astellas Pharma US IncMyrbetriq | $273 | $11,80614 claims |
| AbbVieSynthroid | $549 | $2,29439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Andover
- Paula WorleyAndover$68K
- Lindsay LandersAndover$38K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.